Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma (Nasdaq: PPCB) reported preclinical pancreatic cancer findings for PRP alone and combined with galunisertib, a TGF-β pathway inhibitor. PRP reduced proliferation by approximately 50% in both wild-type and gemcitabine-resistant BxPC-3 cells; the combination reduced it by 75% and 66%, respectively. The additional reduction was statistically significant only in wild-type cells.
Both treatments reduced colony formation and invasion. PRP alone showed greater selectivity between cancer-associated and normal-associated fibroblasts, cells in surrounding tissue. Adding galunisertib increased suppression of some cancer-associated responses but also affected normal-associated cells more. Gene-expression changes did not establish complete reversal of the transition toward more mobile cell behavior. An Australian patent application was filed for the combination; further validation in more complex models is planned.
Propanc Biopharma (Nasdaq: PPCB) is advancing analytical development for its planned Phase 1b first-in-human PPC-001 study in up to 50 patients. The planned study targets advanced cancer patients with solid tumors.
Testing detected both proenzyme components, trypsinogen and chymotrypsinogen, without evidence of significant degradation during investigated handling periods. Follow-up testing covered three human donors; September testing showed recovery generally exceeding 85% after 60 minutes at room temperature. Mass spectrometry measured both components in serum and plasma. Labelled reagents showed no detectable degradation under tested labelling conditions or after one day at 4°C.
Feasibility work continues on two anti-drug antibody assays, which measure immune responses to treatment. Assay establishment and validation depend on successful feasibility assessment. Propanc plans further optimization of methods measuring drug components in clinical samples.
Propanc Biopharma (Nasdaq: PPCB) is advancing preparations for a planned Phase 1b first-in-human study of PRP in up to 50 advanced cancer patients.
The proposed multicenter, open-label study would use dose escalation and expansion in advanced or metastatic solid tumors. Final protocol documentation is targeted for early November 2026, with additional stability information scheduled for the Investigator’s Brochure during November. Propanc targets first-site ethics submission in November, regulatory activities in January 2027, and first-site initiation followed by first patient screening in February 2027. That timing depends on completing clinical, regulatory, ethics and operational requirements.
Site assessments, vendor contracting and study systems preparation remain underway. PRP has US FDA Orphan Drug Designation in pancreatic cancer; pancreatic ductal adenocarcinoma is its lead indication.
Propanc Biopharma (PPCB) announced preclinical findings showing its PRP candidate altered chemotherapy-resistant pancreatic cancer cells and supported subsequent chemotherapy sensitivity. In resistant-cell models, PRP reduced proliferation by ~50–54% and long-term colony-forming survival by up to 59%. Invasive capacity fell 47–81%, alongside changes toward a more epithelial, less migratory cell state.
A separate peer-reviewed pilot study reported an 85.9% reduction in mean tumor weight at the higher dose in a pancreatic mouse model and ~50% tumor-weight inhibition in an ovarian model. Propanc plans a Phase 1b first-in-human study for Q1 2027, expected to enroll up to 50 patients with advanced solid tumors in Australia. Manufacturing, drug-level assay validation and clinical preparations are advancing. PRP holds FDA Orphan Drug Designation for pancreatic cancer.
Propanc Biopharma (PPCB) approved a 1-for-10 reverse stock split, anticipated to take effect before market open on October 26, 2026. Every 10 outstanding common shares will automatically combine into one share. The corrected effective date replaces October 19, 2026.
The company said the split aims to restore compliance with Nasdaq’s continued listing standards, including its $1.00 minimum bid price requirement, and support growth plans. Propanc is preparing for a Phase 1b first-in-human study of PRP in up to 50 advanced cancer patients with solid tumors in the first quarter of 2027.
Propanc Biopharma (Nasdaq: PPCB) announced preclinical findings showing its PRP formulation altered chemotherapy-resistant pancreatic cancer cells and their subsequent chemotherapy response. PRP alone reduced proliferation by 54% in resistant cells and 50% in wild-type cells. PRP pre-treatment followed by chemotherapy produced the study’s strongest functional response. Separate experiments combining PRP with a TGF-β inhibitor achieved 80% invasion inhibition in resistant cells.
The research, involving the Universities of Jaén and Granada, examined cell behavior and gene activity. Results showed changes in programs associated with resistance, invasion and susceptibility to cell death, with responses differing between tumor models. Propanc plans a Phase 1b first-in-human study in Q1 2027 for advanced cancer patients with solid tumors. Further validation in clinically relevant models is planned to assess whether the resistance-remodeling effect can benefit patients.
Propanc Biopharma (PPCB) announced publication of a peer-reviewed pilot study evaluating PRP in pancreatic and ovarian cancer models and reporting patient survival observations.
Published in Scientific Reports, the study evaluated trypsinogen and chymotrypsinogen A at a 1:6 ratio. Daily intravenous PRP reduced mean tumor weight by 85.9% at the higher dose in a pancreatic cancer model and approximately 50% across two doses in an ovarian cancer model, with no treatment-related adverse clinical events. Separately, 46 patients with advanced cancers received a rectal proenzyme formulation through the UK Specials Scheme. Mean survival was 9.0 months versus mean expected survival of 5.6 months; 19 patients exceeded predicted life expectancy. No severe or serious adverse events related to rectal administration, hematologic toxicity, or allergic reactions were observed.
Propanc Biopharma (PPCB) reported preclinical pancreatic cancer results for PRP, including more than 90% mean tumor growth inhibition versus vehicle.
In advanced pancreatic ductal adenocarcinoma models, intravenous PRP extended median overall survival more than 2.5-fold versus controls, reduced liver and peritoneal metastases, and reduced fibrosis and markers of epithelial-mesenchymal transition, a change in cell behavior. Chemotherapy-resistant cells became more sensitive to gemcitabine plus nab-paclitaxel. PRP has FDA orphan drug designation for pancreatic cancer. Propanc sees it as a potential combination or sequential partner, rather than a substitute, for the FDA-approved RAS inhibitor daraxonrasib.
The company plans a Phase 1b first-in-human study in Q1 2027, expected to enroll up to 50 advanced solid-tumor patients across Australia. Prior compassionate-use observations involved related proenzyme formulations.
Propanc Biopharma (PPCB) reported a narrower annual loss and outlined plans for a Phase 1b study of PRP. The study is planned to start in the first quarter of 2027, with a first patient visit scheduled for April. It would enroll up to 50 patients with advanced solid tumors in Australia. In animal models of pancreatic cancer, PRP produced greater than 90% mean tumor growth inhibition versus controls and extended median survival by more than 2.5-fold.
For the year ended June 30, 2026, net loss narrowed to $18,862,710 from $58,923,300; revenue remained at zero. Annual gross proceeds raised totaled $7.5 million, including a public offering of 1,000,000 shares at $4.00 each. Cash stood at $832,006 at June 30, and a further $2.0 million was received from the Series C facility afterward. Total liabilities fell to $3,378,251 from $5,725,616. Propanc also authorized up to $5.0 million in share repurchases and completed a $500,000 first tranche.
Propanc Biopharma (PPCB) reported new preclinical pancreatic ductal adenocarcinoma (PDAC) data for its lead candidate PRP, showing more than 90% mean tumor-growth inhibition and over 2.5-fold median overall survival extension versus controls in orthotopic and patient-derived xenograft models.
PRP, an intravenous fixed-ratio proenzyme combination, is described as non-cytotoxic and differentiation-based, targeting epithelial-mesenchymal transition, cancer stem cells, fibrosis, and the tumor microenvironment rather than RAS itself. The company contrasts this profile with Erasca’s oral pan-RAS molecular glue ERAS-0015 and daraxonrasib, positioning PRP as potentially complementary. PRP holds FDA Orphan Drug Designation for pancreatic cancer, with a multicenter Phase 1b first-in-human study in advanced solid tumors planned to start dosing in February 2027.